Abstract
Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Keywords: Cardiac stem cells, chemotherapy-induced cardiotoxicity, pluripotent stem cells, preclinical models, cardiomyopathy, human embryomic stem cell.
Current Drug Targets
Title:Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Volume: 18 Issue: 6
Author(s): Rosalinda Madonna*, Christian Cadeddu, Martino Deidda, Paolo Spallarossa, Concetta Zito and Giuseppe Mercuro*
Affiliation:
- Dipartimento di Scienze Mediche Mario Aresu, Universita of Cagliari,Italy
- Department of Medical Sciences “Mario Aresu”, University of Cagliari, Cagliari,Italy
Keywords: Cardiac stem cells, chemotherapy-induced cardiotoxicity, pluripotent stem cells, preclinical models, cardiomyopathy, human embryomic stem cell.
Abstract: Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Export Options
About this article
Cite this article as:
Madonna Rosalinda*, Cadeddu Christian, Deidda Martino, Spallarossa Paolo, Zito Concetta and Mercuro Giuseppe *, Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells, Current Drug Targets 2017; 18 (6) . https://dx.doi.org/10.2174/1389450117666160401125404
DOI https://dx.doi.org/10.2174/1389450117666160401125404 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art
Current Radiopharmaceuticals Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Echocardiogram versus Cardiac Magnetic Resonance Imaging for the Diagnosis of Non-compaction Cardiomyopathy – A Case Report
New Emirates Medical Journal Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Current Pharmaceutical Design Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard?
Cardiovascular & Hematological Agents in Medicinal Chemistry Enterovirus D-68 Molecular Virology, Epidemiology, and Treatment: an Update and Way Forward
Infectious Disorders - Drug Targets DNAJ Proteins and Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Advancement of Mechanisms of Coxsackie Virus B3-Induced Myocarditis Pathogenesis and the Potential Therapeutic Targets
Current Drug Targets Toll-Like Receptors and Myocardial Ischemia/Reperfusion, Inflammation, and Injury
Current Cardiology Reviews Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design The Critical Role of Insulin-Like Growth Factor-1 Isoforms in the Physiopathology of Skeletal Muscle
Current Genomics Role of Chymase in Preeclampsia
Current Vascular Pharmacology What Does a Pediatrician Need to Know About Chronic Diarrhea?
Current Pediatric Reviews Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery